drugset / Trial / NCT03308448

Traumatic Optic Neuropathy Treatment Trial 2

NCT03308448

RandomizedParallel-groupDouble-blindTreatment

Summary

After introducing intravenous erythropoietin (EPO) as an option for treatment of patients with indirect traumatic optic neuropathy in 2011 and publishing non inferiority trial in Oct.2017), TONTT2 is aiming to find out the best dose and timing of EPO administration in this group of patients.

Timeline

Start
2018-01-06
Primary completion
2022-08-06
Completion
2023-03-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator epoetin alfa Protein / enzyme biologic 900 iu/kg Intravenous
Comparator epoetin alfa Protein / enzyme biologic 1800 iu/kg Intravenous
Comparator epoetin alfa Protein / enzyme biologic 3600 iu/kg Intravenous

Indications